A Pan-Cancer Analysis of CD161, a Potential New Immune Checkpoint

被引:64
|
作者
Zhou, Xiaohan [1 ]
Du, Jun [2 ]
Liu, Chengdong [3 ]
Zeng, Hanyi [3 ]
Chen, Yuting [1 ]
Liu, Li [3 ]
Wu, Dehua [1 ]
机构
[1] Southern Med Univ, Nanfang Hosp, Dept Radiat Oncol, Guangzhou, Peoples R China
[2] Chinese Acad Med Sci & Peking Union Med Coll, Canc Hosp, Natl Clin Res Ctr Canc, Natl Canc Ctr, Beijing, Peoples R China
[3] Southern Med Univ, Nanfang Hosp, Dept Infect Dis, Guangzhou, Peoples R China
来源
FRONTIERS IN IMMUNOLOGY | 2021年 / 12卷
基金
国家重点研发计划;
关键词
TCGA; immune microenvironment; CD161; immune checkpoints; immunotherapy; REGULATORY T-CELLS;
D O I
10.3389/fimmu.2021.688215
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background CD161, encoded by killer cell lectin-like receptor B1 gene, is a newly reported candidate inhibitor of tumour-infiltrating T cells. Antibody-mediated CD161 blockade enhances T cell-mediated killing of cancer cells in vitro and in vivo in several tumour types. We evaluated the role of CD161 using The Cancer Genome Atlas (TCGA) Pan-Cancer Data. Methods CD161 expression was analysed using RNAseq data from TCGA and the Genotype-Tissue Expression (GTEx) database. HPA, GeneCards, and String database were used to explore the protein information of CD161. The prognostic value of CD161 was analysed using clinical survival data from the TCGA. Enrichment analysis of CD161 was conducted using the R package "clusterProfiler". We downloaded the immune cell infiltration score of TCGA samples from published articles and online databases and performed a correlation analysis between immune cell infiltration levels and CD161 expression. We further assessed the association between CD161 and immune checkpoints, immune activating genes, immunosuppressive genes, chemokines, and chemokine receptors. Findings CD161 was differentially expressed and predicted better survival status in most tumour types in TCGA. In addition, CD161 expression was significantly associated with immunoregulatory interactions between lymphoid and non-lymphoid cells. CD161 expression was closely correlated with T cell infiltration, immune checkpoints, immune activating genes, immunosuppressive genes, chemokines, and chemokine receptors. Interpretation Our results suggest that CD161 is a potential cancer biomarker. CD161 might synergize with other immune checkpoints to regulate the immune microenvironment, which could be applied in the development of new-targeted drugs for immunotherapy. Funding This work was supported by the National Nature Science Foundation of China (grant numbers 81773008, 81672756, 81872399, 81972897), the Guangdong Province Universities and Colleges Pearl River Scholar Funded Scheme (2015), the Natural Science Foundation of Guangdong Province (grant number 2017A030311023), the Local Innovative and Research Teams Project of Guangdong Pearl River Talents Program: 2017BT01S131 and the Guangzhou Technology Project (grant number 201804010044), National Key R&D Program of China (Grant Nos. 2020YFC2006400), Key-Area Research and Development Program of Guangdong Province (2019B020227004).
引用
收藏
页数:11
相关论文
共 50 条
  • [1] CD161, a promising Immune Checkpoint, correlates with Patient Prognosis: A Pan-cancer Analysis
    Ye, Wenrui
    Luo, Cong
    Li, Chenglong
    Liu, Zhixiong
    Liu, Fangkun
    JOURNAL OF CANCER, 2021, 12 (21): : 6588 - 6599
  • [2] A Pan-cancer Analysis of CREBBP as a potential predictor for immune checkpoint therapy.
    Li, Jiaping
    Fan, Wenzhe
    Zhao, Yue
    Xue, Miao
    Chen, Tingting
    Xie, Wenzhuan
    Huang, Mengli
    CANCER RESEARCH, 2021, 81 (13)
  • [3] Pan-cancer analysis predicts MBOAT2 as a potential new ferroptosis related gene immune checkpoint
    Xie, Yuhan
    Zhang, Shichao
    Wu, Yu
    Qi, Yuanjiong
    Qi, Shiyong
    Chen, Xiuju
    Chen, Bing
    DISCOVER ONCOLOGY, 2025, 16 (01)
  • [4] GPR65 as a potential immune checkpoint regulates the immune microenvironment according to pan-cancer analysis
    Wang, Liangliang
    Sun, Lele
    Sun, Hao
    Xing, Yunhong
    Zhou, Shidong
    An, Guoshuai
    Li, Jian
    Ren, Kang
    Sun, Junhong
    HELIYON, 2023, 9 (02)
  • [5] A pan-cancer and single-cell sequencing analysis of CD161, a promising onco-immunological biomarker in tumor microenvironment and immunotherapy
    Li, He
    Zhou, Ke
    Wang, Kaiyue
    Cao, Hui
    Wu, Wantao
    Wang, Zeyu
    Dai, Ziyu
    Chen, Shi
    Peng, Yun
    Xiao, Gelei
    Luo, Peng
    Zhang, Jian
    Liu, Zaoqu
    Cheng, Quan
    Zhang, Hao
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [6] A pan-cancer analysis of MUC family genes as potential biomarkers for immune checkpoint therapy.
    Li, Yang
    Duan, Qianqian
    Tan, Yuan
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [7] A pan-cancer analysis of KMT2D as a potential biomarker for immune checkpoint therapy
    Guan, X.
    Cai, S.
    Wu, X.
    Chen, Y.
    Deng, H.
    Zhong, X.
    Chen, T.
    Huang, M.
    ANNALS OF ONCOLOGY, 2021, 32 : S847 - S847
  • [8] A pan-cancer analysis of ARID1A as a potential biomarker for immune checkpoint therapy.
    Yang, Dongyong
    Xu, Yuan
    Huang, Linlin
    Guo, Zhifeng
    Fan, Jimin
    Chen, Tingting
    Xie, Wenzhuan
    Huang, Mengli
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [9] A pan-cancer analysis of GRIN2A as a potential biomarker for immune checkpoint therapy.
    Jiang, Mei
    Zhong, Xuefeng
    Huang, Mengli
    CANCER RESEARCH, 2022, 82 (12)
  • [10] A PAN-CANCER META-ANALYSIS OF IMMUNE CHECKPOINT INHIBITOR RESPONSE
    不详
    CANCER DISCOVERY, 2021, 11 (03) : 532 - 532